{"id":"W3042347895","doi":"10.1002/cncr.33033","title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Everolimus; Open label; Randomized controlled trial; Renal cell carcinoma; Internal medicine; Oncology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003985884,0.0005658594,0.001304218,0.0002407073,0.0002907177,0.001186427,0.0006134359,0.000900774,0.002249811],"category_scores_gemma":[0.003407818,0.0002439684,0.002525144,0.0004081826,0.0004015909,0.0008297991,0.0003616192,0.001693095,0.0002881275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009334036,"about_ca_system_score_gemma":0.0008387811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001137084,"about_ca_topic_score_gemma":0.003441301,"domain_scores_codex":[0.9984751,0.0009523159,0.0001030266,0.0001798498,0.0001751553,0.0001144142],"domain_scores_gemma":[0.9973207,0.0008560488,0.001051767,0.0001984915,0.0001743887,0.0003985554],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8890511,0.003014419,0.02457369,0.001272834,0.008635946,0.00007267331,0.0001300853,0.001781075,0.002502541,0.0002281288,0.003626001,0.06511144],"study_design_scores_gemma":[0.7749041,0.08726358,0.1137387,0.0003619257,0.01070511,0.000371461,0.0001246915,0.003043064,0.001567576,0.000559342,0.007275014,0.00008536813],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765905,0.01710336,0.0005509294,0.000595025,0.0001882815,0.0006804432,0.002248824,0.0000504447,0.00199221],"genre_scores_gemma":[0.9904786,0.002642211,0.0006772081,0.0009440127,0.0002069783,0.0006438366,0.003666505,0.0000138278,0.000726802],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003985884,"threshold_uncertainty_score":0.0210796,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03662694787433408,"score_gpt":0.2968996984932093,"score_spread":0.2602727506188752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}